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 Table 1: Data extraction of core model structures from the 14 original modelling studies 
Study 
Model 
type 
Pain measurement 
Pain outcomes 
modelled AEs modelled 
Titration 
considered? 
Treatment 
lines 
modelled 
Cycle 
length 
Time 
horizon 
Model 
replicated 
elsewhere 
Annemans 
et al.14 
Markov 11-point NRS  3 categories of 
pain modelled as 
“mild” (NRS<4), 
“moderate” (NRS 
≥4 and <7) or 
“severe” (NRS≥7) 
Yes, modelled 
as 
discontinuation 
only 
No 1st and 2nd 
line 
 
4 
weeks 
1 year Chevalier et 
al30 
Armstrong 
et al.15 
Markov  Two categories of 
pain reduction: ≥30% 
reduction in pain, 
<30% reduction in 
pain (measurement 
instrument not clear) 
Two categories of 
pain reduction: 
≥30% pain or 
<30% pain 
reduction 
Yes, cost and 
HRQL of 
managing 
headache, 
constipation, 
oedema, 
dizziness, 
somnolence, 
diarrhoea, 
vomiting, rash, 
urine retention, 
nausea, dry 
mouth 
Yes  
1st and 2nd 
line 
 
Monthly 1 year No 
Beard et 
al.16 
Decision 
tree 
Three categories of 
pain reduction: >50% 
pain reduction, 30-
49% pain reduction 
and <30% pain 
reduction or reported 
a 11 point NRS  
Three categories 
of pain reduction: 
>50% pain 
reduction, 30-49% 
pain reduction and 
<30% pain 
reduction 
 
Yes, modelled 
as 
discontinuation 
only 
No 1st, 2nd, 3rd 
and 4th 
line 
NA 6 
months 
No 
Bellows* 
et al.17 
Decision 
tree 
Categorised as <50% 
pain reduction or 
≥50% pain reduction 
Two categories of 
pain relief: “Good” 
pain relief (≥50% 
Yes, costs and 
HRQL relating 
to tolerable, 
No 1st line NA 6 
months 
No 
Study 
Model 
type 
Pain measurement 
Pain outcomes 
modelled AEs modelled 
Titration 
considered? 
Treatment 
lines 
modelled 
Cycle 
length 
Time 
horizon 
Model 
replicated 
elsewhere 
based on daily 
numerical pain scores 
(measurement tool 
not clear) 
reduction)  and 
“poor” pain relief 
(<50% reduction) 
intolerable and 
serious AEs  
Carlos et 
al.*18 
Decision 
tree 
Patient-reported 
subjective pain relief 
of 
‘moderate’ or better, 
or (2) ‘much 
improved’ or better on 
the (PGIC) scale, or 
≥50% reduction in 
pain reduced by 
factor of 1.193 
Two categories of 
pain relief: “good” 
or “poor”  
Yes, costs and 
HRQL relating 
to AEs and 
discontinuation 
from 
intolerable 
AEs included 
No 1st line NA 12 
weeks 
No 
Cepeda 
and 
Farrar19 
Decision 
tree 
Two categories of 
pain relief: reduction 
of ≥50% or <50% 
(measurement 
method not clear) 
Two categories of 
pain relief: “pain 
relief” or “no pain 
relief” 
Yes, costs and 
HRQL 
included for 
major and 
minor AEs 
No 1st line NA 1 
month 
No 
Dakin et 
al.22 
Markov Proportion of patients 
experiencing “much” 
or “very much” 
improved on PGIC or 
CGIC, or “moderate” 
or “greater” 
improvement on 
PGASI or PGAI 
Two categories of 
pain relief: 
“Responders” and 
“insufficient pain 
relief” 
Yes, costs and 
HRQL relating 
to tolerable 
and intolerable 
AEs 
Yes 1st and 2nd 
line 
30 days 6 
months 
Ritchie, 
Liedgens &  
Nuijten 23, 
Dakin et al. 
32 
De-Salas-
Cansado 
et al.27 
Decision 
tree 
HRQL differences by 
treatment arm 
incorporated directly 
from analysis of  
EQ-5D data from 
Change in EQ-5D 
score from 
baseline 
calculated in 
matched pairs 
Not modelled No 1st line NA 12 
weeks 
De-Salas-
Cansado et 
al. 3 
Study 
Model 
type 
Pain measurement 
Pain outcomes 
modelled AEs modelled 
Titration 
considered? 
Treatment 
lines 
modelled 
Cycle 
length 
Time 
horizon 
Model 
replicated 
elsewhere 
matched analysis of 
paired samples from 
observational study 
analysis 
Gordon et 
al.4 
Discrete 
individual 
simulation 
11-point NRS Level of pain (11 
point scale) 
 
Yes, costs and 
HRQL and 
withdrawal 
modelled in 
one arm of 
study 
No 1st and 2nd 
line 
Weekly 5 years Prettyjohns 
et al 31 
NICE 
20135 
Decision 
tree 
Three categories of 
pain reduction; >50% 
pain reduction, 30-
49% pain reduction 
and <30% pain 
reduction† 
Three categories 
of pain reduction; 
>50% pain 
reduction, 30-49% 
pain reduction and 
<30% pain 
reduction 
Yes, costs and 
HRQL of 
nausea and 
dizziness 
modelled 
No 1st line  NA 20 
weeks 
No 
O’Connor 
et al.*20 
Decision 
tree 
Binary definition of 
pain improvement; 
based on “much 
improved” or better in 
PGIC or patient-
reported subjective 
pain relief defined as 
“moderate” or better 
Two categories of 
pain relief: “good 
pain relief” and 
“poor pain relief” 
Yes, HRQL 
incorporated 
with respect to 
minor, 
intolerable and 
serious AEs. 
Costs explored 
in SA 
No 1st line NA 3 
months 
No 
O’Connor 
et al.*21 
Decision 
tree 
Binary definition of 
pain improvement; 
based on “much 
improved” or better in 
PGIC or patient-
reported subjective 
pain relief defined as 
“moderate” or better 
Two categories of 
pain relief: “good 
pain relief” and 
“poor pain relief” 
Yes, costs and 
HRQL were 
incorporated 
with respect to 
minor, 
intolerable and 
serious AEs 
No 1st line NA 3 
months 
No 
Study 
Model 
type 
Pain measurement 
Pain outcomes 
modelled AEs modelled 
Titration 
considered? 
Treatment 
lines 
modelled 
Cycle 
length 
Time 
horizon 
Model 
replicated 
elsewhere 
Smith and 
Roberts28 
Markov Two categories of 
pain reduction: ≥50% 
or 
<50%(measurement 
method not clear) 
Two categories of 
pain reduction: 
≥50% or <50% 
Yes, costs and 
HRQL 
modelled with 
respect to 
severe side 
effects leading 
to 
discontinuation 
No 1st, 2nd, 
3rd, 4th 
and 5th 
line 
1 
month 
Lifetime No 
Tarride et 
al.25 
Markov 11-point NRS  3 categories of 
pain modelled as 
“mild”/”none” 
(NRS<4), 
“moderate” (NRS 
≥4 and <7) or 
“severe” (NRS≥7) 
Not modelled No 1st line  1 day 12 
weeks 
Rodriguez 
et al. 24 , 
Athanasakis 
et al.  29 
Key: 
AE, adverse event; CGIC, Clinician Global Impression of Change; EQ-5D, European Quality of Life – 5 Dimensions; HRQL, health-related quality of 
life; NA, not applicable; NRS, numerical rating scale; PCIG, Patient Global Impression of Change; PGAI, Physician Global Assessment of 
Improvement; PGASI, Patient Global Assessment of Self-Improvement; SA, sensitivity analysis;  
Notes: 
* These studies were derived from Cepeda and Farrar19, but variations existed in the model structure; as such, they were included as original 
structures within the review. 
† The systematic review used to inform the meta-analysis conducted by NICE to obtain efficacy estimates within their model included the following 
pain measurements: visual analogue scales, verbal rating scales, numerical rating scales, proportion of patients attaining particular level of global 
improvement of pain relief.  
 
